RGNX
REGENXBIO Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.92
−3.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 174.5M | 170.4M | 83.3M | 90.2M | 112.7M |
| Cost of Revenue | 79.9M | 20.3M | 33.6M | 37.2M | 54.5M |
| Gross Profit | 94.6M | 150.1M | 49.8M | 53.0M | 58.2M |
| Operating Expenses | |||||
| R&D Expense | 229.1M | 228.3M | 208.5M | 232.3M | 242.5M |
| SG&A Expense | 85.6M | 82.9M | 76.6M | 88.5M | 85.3M |
| General & Admin Expense | 85.6M | 82.9M | 76.6M | 88.5M | 85.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (55.9M) | 179.0K | (2.0M) | 397.0K | (6.7M) |
| Total Operating Expenses | 258.8M | 311.3M | 283.1M | 321.2M | 321.1M |
| Cost and Expenses | 338.6M | 331.6M | 316.7M | 358.4M | 375.6M |
| Operating Income (EBIT) | (164.1M) | (161.2M) | (233.3M) | (268.1M) | (262.9M) |
| Non-Operating | |||||
| Interest Income | 1.3M | 12.3M | 174.0K | 25.0K | 342.0K |
| Interest Expense | 41.9M | 45.0M | 12.7M | 6.9M | 23.3M |
| Net Interest Income | (40.7M) | (32.7M) | (12.5M) | (6.8M) | (22.9M) |
| Other Non-Op Income/Expense | (32.3M) | (32.7M) | 6.2M | 4.5M | (17.5M) |
| Non-Operating Income (excl Interest) | (9.7M) | (12.3M) | (18.9M) | (11.3M) | (5.7M) |
| EBT (Pre-Tax Income) | (196.4M) | (193.9M) | (227.1M) | (263.6M) | (280.4M) |
| Income Tax Expense | — | — | — | (152.0K) | (84.0K) |
| Bottom Line | |||||
| Net Income | (196.4M) | (193.9M) | (227.1M) | (263.5M) | (280.3M) |
| Earnings from Cont. Ops | (196.4M) | (193.9M) | (227.1M) | (263.5M) | (280.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (196.4M) | (193.9M) | (227.1M) | (263.5M) | (280.3M) |
| Per Share | |||||
| Basic EPS | ($3.79) | ($3.76) | ($4.59) | ($6.02) | ($6.50) |
| Diluted EPS | ($3.79) | ($3.76) | ($4.59) | ($6.02) | ($6.50) |
| Revenue Per Share | $3.30 | $3.30 | $1.68 | $2.06 | $2.61 |
| Shares | |||||
| Basic Shares Outstanding | 52.8M | 51.6M | 49.5M | 43.7M | 43.2M |
| Diluted Shares Outstanding | 53.0M | 51.6M | 49.5M | 43.7M | 43.2M |
| Profitability Metrics | |||||
| EBITDA | (139.1M) | (133.3M) | (198.2M) | (239.5M) | (244.2M) |
| D&A | 15.4M | 15.6M | 16.2M | 17.3M | 12.9M |
| EBIT | (154.5M) | (148.9M) | (214.4M) | (256.8M) | (257.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026